Contribution of Surgical Proceduresand Biomarkers to Diagnosisand Prognosis in Pleural Effusions

Research Article


  • Fatoş Kozanlı Kahramanmaraş Sütçü İmam Üniversitesi



Pleural Effusion,, Transudate,, Exudate,, Lactate Dehydrogenase.


Itroduction: Pleural effusion (PE) is the accumulation of pathological amounts of fluid in the pleural space. Initial evaluation should include transudate/exudate separation of the fluid by thoracentesis.

Objective: A significant percentage of pleural effusions goun diagnosed. In our study, it was aimed to contribute to the literature by retrospectively examining the cases with pleural effusion, evaluating their demographic characteristics, etiology, diagnosis and treatment methods, biochemical markers, causes of morbidity and mortality.

Methods:  In our study, the files of 175 patients who were diagnosed with pleural effusion were reviewed retrospectively. Age, gender, comorbidity, approach to pleural fluid, analysis of venous blood and pleural fluid, diagnosis of pleural fluid, morbidity and mortality were evaluated in our cases.

Results: Women were 55 men and 110 people. The female to male ratio was 1/2. Cases with benign pleural effusion were 68.5% and cases with MPE were 31.5%.  The most common cause of MPE  was lung cancer in 21 (12%) cases. Serum lactate dehydrogenase (LDH) and pleural fluid LDH were significantly higher in the malignant group. The age of the patients and the rate of additional disease were significantly higher in the mortality group.

Conclusion: Exudative effusions are usually caused by infection, malignancy and inflammatory diseases such as rheumatoid arthritis. The most common causes of MPE are lung cancers. Intervention should be decided by the clinical characteristics of the patient. Surgical procedure shave a high diagnostic value. Biochemical markers such as serum/plasma LDH and protein will contribute to the differential diagnosis.


Jany B, Welte T. Pleural Effusion in Adults-Etiology, Diagnosis, and Treatment. Dtsch Arztebl Int. 2019;116(21):377-386.

Hooper C, Lee YCG, Maskell N. Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65.

Beaudoin S, Gonzalez AV. Evaluation of the patient with pleural effusion. CMAJ. 2018;190(10):E291-E295.

Mercer RM, Corcoran JP, Porcel JM, et al. Inter preting pleural fluid results. Clin Med (Lond). 2019;19(3):213-217.

Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med.1992;34:718-21.

Thomas R, Jenkins S, Eastwood PR, et al. Physiology of breathlessness associated with pleural effusions. Curr Opin PulmMed. 2015;21:338-354.

Saguil A, Wyrick K, Hallgren J. Diagnostic approach to pleural effusion. Am Fam Physician. 2014;90(2):99-104.

Havelock T, Teoh R, Laws D, et al. Pleural procedures and thoracic ultrasound: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii61-76.

Romero-Candeira S, Hernández L, Romero-Brufao S, et al. Is it meaning ful to use biochemical parameters to discriminate between transudative and exudative pleural effusions?. Chest. 2002;122:1524-9.

Michaud G, Berkowitz DM, Ernst A. Pleuroscopy for diagnosis and therapy for pleural effusions. Chest. 2010;138:1242-6.

Lee P, Colt HG. Pleuroscopy in 2013. Clin Chest Med. 2013;34:81-91.

Pastré J, Roussel S, Israël Biet D, et al Orientation diagnostique et conduite à tenirdevant un épanchement pleural. Rev Med Interne. 2015;36(4):248-55.

Light RW. Pleural Diseases. 4th ed. Baltimore: Lipincott Williams & Wilkins; 2001.

Li D, Ajmal S, Tufail M et al. Modern day management of a unilateral pleural effusion. Clin Med (Lond). 2021;21(6):e561-e566.

Gayen S. Malignant Pleural Effusion: Presentation, Diagnosis, and Management. Am J Med. 2022;135(10):1188-1192.

Walker SP, Morley AJ, Stadon L, et al. Nonmalignant pleural effusions. Chest. 2017;151:1099–1105.

Heffner JE. Diagnosis and management of malignant pleural effusions. Respirology. 2008;13(1):5-20.

Marel M, Stastny B, Melinova L, et al. Diagnosis of pleural effusions. Experience with clinical studies, 1986 to 1990. Chest. 1995;107:1598-603.

Na MJ. Diagnostic tools of pleural effusion. Tuberc Respir Dis (Seoul). 2014;76(5):199-210.

Penz E, Watt KN, Hergott CA, et al. Management of malignant pleural effusion: challenges and solutions. Cancer Manag Res. 2017;23(9):229-241.

Pourhoseingholi MA. Increased burden of colorectal cancer in Asia. World J Gastrointest Oncol. 2012;4(4):68-70.

Torres Udos S, Almeida TE, Netinho JG. Increasing hospital admission rates and economic burden for colorectal cancer in Brazil, 1996-2008. Rev Panam Salud Publica. 2010;28(4):244-8.

Atabey E. Mihalıçcık (Eskişehir) ile Bekilli (Denizli) yöresi lifsi amfibol asbest oluşumları ve akciğer kanseri ilişkisi (Mezotelyoma). 60. Türkiye Jeoloji Kurultayı Bildiri Özleri Kitabı. Ankara: 2007:286-8.

Batungwanayo J, Taelman H, Allen S, et al. Pleural effusion, tuberculosis and HIV-1 infection in Kigali, Rwanda. AIDS. 1993;7:73-9.

Vives M, Porcel JM, Vera MCV, et al. A study of Light’scriteria and possible modifications for distinguishing exudative from transudative pleural effusions. Chest.1996;109:1503-7.

Tokgöz F, Gökşenoğlu N, Bodu Y, et al. Plevral efüzyonlu 240 olgunun retrospektif analizi. Eurasian J Pulmonol. 2014;16:78-83.

Brueckl WM, Herbst L, Lechler A, et al. Predictive and prognostic factors in small celllung carcinoma (SCLC)--analysis from routine clinical practice. Anticancer Res. 2006;26(6C):4825-32.

Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Tumourand Angiogenesis Research Group. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-celllung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer. 2003;89(5):877-85.

Bansal SK, Kaw JL. LDH in macro phages and serum during the development of pulmonary silicosis in therat. Toxicol Lett. 1981.

Nemanič T, Rozman A, Adamič K, et al. Biomarkers in routine diagnosis of pleural effusions. Slovenian Medical Journal. 2018;87(1-2):15-21.

Erdogdu V, Metin M. Parapnomonik Plevral Efuzyon ve Ampiyem. Solunum. 2013;15:69-76.

Koegelenberg CFN, Shaw JA, Irusen EM, et al Contemporary best practice in the management of malignant pleural effusion. Ther Adv Respir Dis. 2018;12:1753466618785098.

Feller-Kopman D, Light R. Pleural disease. New Engl J Med. 2018;378:740–51.

Menéndez R, Torres A, Zalacaín R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004;59:960–965.



How to Cite

Kozanlı, F. (2023). Contribution of Surgical Proceduresand Biomarkers to Diagnosisand Prognosis in Pleural Effusions: Research Article. Acta Medica Ruha, 1(2), 106–115.



Research Articles